
Five-year results from the extended randomized MGTX trial demonstrated that the addition of thymectomy to prednisone leads to long-lasting lower quantitative myasthenia gravis (QMG) scores and prednisone dosing.
Five-year results from the extended randomized MGTX trial demonstrated that the addition of thymectomy to prednisone leads to long-lasting lower quantitative myasthenia gravis (QMG) scores and prednisone dosing.
Molecular minimal residual disease (MRD) testing during the first 4 days of induction therapy does not differentiate responders and nonresponders and should not be used in predicting clinical response for patients with acute myeloid leukemia (AML), according to the results from a recent study.
Results from a recent study showed that only age affects cortical thickness or volume, and intracranial volume affects cortical volume in migraine.
Patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy tend to have poor health-related quality of life (HRQoL) scores that are independent predictors of poor survival, a recent study reported.
According to a recent study, the out-of-pocket clinical costs and capitalized clinical costs per approved drug were both lower for orphan drugs compared with nonorphan drugs.
Long noncoding RNAs (lncRNAs) are involved in the pathogenesis of b-cell precursor acute lymphoblastic leukemia (BCP-ALL) and contribute to the stratification of BCP-ALL subtypes, according to results from a recent study.
A recent review outlined a vast array of biomarkers that may have clinical implications on the treatment and prognosis of colorectal cancer (CRC).
A recent study using the 2016 genome-wide association study (GWAS) identified that vascular mechanisms, but also neuronal and metal ion homeostasis, may play a role in migraine susceptibility.
Nonheadache and headache specialists have moderate levels of agreement in classifying common chronic headache disorders after using the telephone classification interview model, according to a study.
A study of 3 assessments for patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab are examined.
Two recent studies analyzed patients with multiple myeloma to identify factors that impacted response to therapy.
Patients with mitochondrial disease have a significantly higher cost burden compared with the general population, according to the results of a recent retrospective claims analysis.
Based on 2 randomized, placebo-controlled studies, the FDA approved romiplostim (Nplate) for pediatric patients 1 year and older with immune thrombocytopenia (ITP) for at least 6 months who do not have sufficient response to other treatments, including corticosteroids, splenectomy, and immunoglobulins.
Patients who have 4 or more migraine days per month and have failed on prophylactic treatment experience reduced quality of life, work productivity, and social activity involvement.
Published results confirm the efficacy of tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma.
There is a lack in correlation between circulating tumor DNA (ctDNA) and bone marrow for minimal residual disease (MRD) by next generation sequencing (NGS) using immunoglobulin genes in patients with multiple myeloma, according to results of a recent study.
Patients with progressive, symptomatic, or recurrent desmoid tumors who received sorafenib have significantly improved progression-free survival (PFS) rates at 1 and 2 years compared with patients who received placebo, according to the results of a recent phase 3 trial.
Maintenance therapy with lenalidomide remains a standard of care for patients with multiple myeloma. However, optimizing maintenance therapy in this setting is required as a result of lenalidomide’s lack of overall survival benefit and improvement in outcomes for patients with high-risk cytogenic abnormalities, according to a recent study.
A phase 2 trial demonstrated that the regimen of rituximab, bortezomib, bendamustine, and dexamethasone is a viable treatment option for older patients with mantle cell lymphoma (MCL), and highlighted the usefulness of using minimal residual disease (MRD) to guide early and late clinical decisions.
Patients with migraine, patent foramen ovale (PFO), and atrial septal aneurysm (ASA) have more frequent ischemic brain lesions, migraine with aura, and larger PFO sizes than patients with migraines and PFO without ASA, according to the results of a recent study.
Patients with a history of migraine are more likely to develop spontaneous coronary artery dissection at a younger age, have depression, and post-SCAD chest pains compared with patients without a migraine history, according to the results of a recent study.
A phase 1 trial by showed that decitabine with ruxolitinib was generally well tolerated and displayed promising clinical efficacy in patients with accelerated or blast-phase myeloproliferative neoplasms (MPN-AP/BP).
A genetic risk variant, rs7665090G, located near NFKB1, on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis (MS), according to the results of a recent study.
Children with Hodgkin lymphoma who are treated during childhood and survive to adulthood have higher incidence rates of breast, lung, colorectal, and thyroid cancer than the general population, according to a recent study.
Patients with prognostic characteristics including higher-grade tumors, progesterone receptor (PgR)–negative tumors, liver metastases, and shorter treatment-free intervals derived a greater benefit from the addition of abemaciclib to endocrine therapy (ET) compared with ET alone, according to a recent study.
Incidence of febrile neutropenia, hospitalizations, and chemotherapy dose reductions and/or delays were similar between short- and long-acting granulocyte-colony stimulating factors, according to a meta-analysis of randomized controlled trials.
Patients with advanced cutaneous melanoma who are responsive to nivolumab (Opdivo) have higher serum levels of soluble CD163 (sCD163) compared with nonresponders, according to the results of a recent study.
Women who breastfed for longer than 6 months had a smaller waist circumference and body mass index (BMI) compared with women who have not breastfed or have breastfed for a shorter duration, according to the results of a recent study.
Data from 3 erenumab clinical trials of patients with migraine have identified that an increase in the frequency of monthly migraine days leads to an increase in acute medication use and productivity loss.
Published: August 29th 2018 | Updated:
Published: September 29th 2018 | Updated:
Published: October 8th 2018 | Updated:
Published: October 8th 2018 | Updated:
Published: October 5th 2018 | Updated:
Published: October 11th 2018 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.